PapersFlow Research Brief
Occupational and environmental lung diseases
Research Guide
What is Occupational and environmental lung diseases?
Occupational and environmental lung diseases encompass pulmonary disorders induced by workplace and environmental exposures, prominently including malignant pleural mesothelioma linked to asbestos and fibrotic conditions such as idiopathic pulmonary fibrosis and diffuse pleural mesothelioma.
The field includes 72,464 works focused on malignant pleural mesothelioma, BAP1 mutations, asbestos exposure, immunotherapy, occupational carcinogens, genetic predisposition, radiation therapy, tumor suppressor genes, pleurectomy/decortication, and diagnostic markers. Key research addresses fibrosis mechanisms, with Wynn (2007) defining fibrosis by excess extracellular matrix deposition from chronic inflammation. Classifications and guidelines for idiopathic interstitial pneumonias and pulmonary fibrosis have been updated, as in Travis et al. (2013) and Raghu et al. (2022).
Topic Hierarchy
Research Sub-Topics
Malignant Pleural Mesothelioma
This sub-topic investigates epidemiology, pathogenesis, and multimodal treatment of mesothelioma linked to asbestos. Researchers study tumor biology, staging, and survival outcomes.
Asbestos Exposure Effects
Studies dose-response relationships, fiber types, and latency in asbestos-induced lung diseases including asbestosis and mesothelioma. Includes exposure assessment and risk modeling.
BAP1 Tumor Suppressor in Mesothelioma
Focuses on germline and somatic BAP1 mutations predisposing to mesothelioma and other cancers. Research explores functional impacts and diagnostic screening.
Mesothelioma Immunotherapy
Examines checkpoint inhibitors, adoptive therapies, and vaccine trials in mesothelioma treatment. Studies biomarkers and combination strategies with chemotherapy.
Pleurectomy Decortication Surgery
Evaluates this lung-sparing surgery for mesothelioma, including patient selection, techniques, and survival compared to extrapleural pneumonectomy. Perioperative outcomes are analyzed.
Why It Matters
Occupational and environmental lung diseases drive significant morbidity from asbestos-related malignancies, with Wagner, Sleggs, and Marchand (1960) documenting 33 cases of diffuse pleural mesothelioma in the North Western Cape Province, all but one linked to crocidolite asbestos exposure in the Asbestos Hills. Chemotherapy advances include Vogelzang et al. (2003), whose phase III trial showed pemetrexed plus cisplatin improved median survival to 12.1 months versus 9.3 months with cisplatin alone in 448 malignant pleural mesothelioma patients. Fibrosis research by Wynn (2007) and Wynn and Ramalingam (2012) identifies therapeutic targets for fibrotic diseases, while Travis et al. (2013) updates idiopathic interstitial pneumonia classification to guide diagnosis in clinical practice. Raghu et al. (2022) provides ATS/ERS/JRS/ALAT guidelines for idiopathic pulmonary fibrosis management, addressing progression in interstitial lung diseases.
Reading Guide
Where to Start
"Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province" by Wagner, Sleggs, and Marchand (1960), as it provides foundational evidence linking crocidolite asbestos exposure to 33 cases of mesothelioma, establishing occupational causation basics.
Key Papers Explained
Wynn (2007) "Cellular and molecular mechanisms of fibrosis" lays mechanistic groundwork for fibrotic scarring from chronic stimuli like asbestos; Wynn and Ramalingam (2012) "Mechanisms of fibrosis: therapeutic translation for fibrotic disease" builds by translating these into therapies. Travis et al. (2013) "An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias" classifies related interstitial pneumonias; Raghu et al. (2022) "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline" extends to updated fibrosis guidelines. Vogelzang et al. (2003) "Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma" applies to treatment.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Frontiers center on immunotherapy, genetic predisposition via BAP1 mutations, and diagnostic markers for malignant pleural mesothelioma, as emphasized in the 72,464 works cluster, though no recent preprints detail new breakthroughs.
Papers at a Glance
Frequently Asked Questions
What defines fibrosis in occupational lung diseases?
Fibrosis is defined by the overgrowth, hardening, and/or scarring of tissues due to excess deposition of extracellular matrix components including collagen. Wynn (2007) attributes this to chronic inflammatory reactions induced by persistent stimuli such as environmental exposures. This process underlies conditions like idiopathic pulmonary fibrosis observed in occupational settings.
How does asbestos exposure cause pleural mesothelioma?
Asbestos exposure, particularly crocidolite, causes diffuse pleural mesothelioma, as shown in 33 cases (22 males, 11 females, ages 31-68) from the North Western Cape Province where all but one had probable exposure in the Asbestos Hills. Wagner, Sleggs, and Marchand (1960) link this occupational carcinogen directly to primary malignant pleural tumors. The association persists in research on malignant pleural mesothelioma.
What is the standard chemotherapy for malignant pleural mesothelioma?
Pemetrexed in combination with cisplatin is the standard, based on a phase III trial in patients with median survival of 6-9 months. Vogelzang et al. (2003) reported improved survival to 12.1 months versus 9.3 months with cisplatin alone in 448 patients. This regimen addresses poor prior chemotherapy responses in this rapidly progressing malignancy.
What updates exist for idiopathic interstitial pneumonias classification?
The 2013 ATS/ERS statement updates the 2002 international multidisciplinary classification of idiopathic interstitial pneumonias. Travis et al. (2013) outline advances from the past decade and areas for future investigation. It supplements prior documents for improved diagnostic accuracy in pulmonary medicine.
What guidelines address idiopathic pulmonary fibrosis progression?
The 2022 ATS/ERS/JRS/ALAT guideline updates prior idiopathic pulmonary fibrosis recommendations and covers progressive pulmonary fibrosis in adults with interstitial lung diseases. Raghu et al. (2022) provide clinical practice directives based on recent evidence. It targets management in patients showing fibrosis progression.
What role do IARC monographs play in evaluating occupational carcinogens?
IARC Monographs evaluate carcinogenic risks to humans from occupational and environmental agents like asbestos. Zuckerman (1995) and Hopkins (1989) contribute to assessments linking exposures to lung diseases including mesothelioma. These inform public health responses to viral hepatitis and other risks, though focused on carcinogens.
Open Research Questions
- ? How do BAP1 mutations interact with asbestos exposure in malignant pleural mesothelioma pathogenesis?
- ? What therapeutic strategies can target tumor suppressor genes in occupational lung cancers?
- ? How effective is immunotherapy combined with pleurectomy/decortication for pleural mesothelioma?
- ? What diagnostic markers best predict progression from environmental exposures to fibrotic lung diseases?
- ? How do genetic predispositions modify risks of radiation therapy-induced lung fibrosis?
Recent Trends
The field maintains 72,464 works with no specified 5-year growth rate; Raghu et al. represents the most recent top-cited update on idiopathic pulmonary fibrosis guidelines, addressing progression in interstitial lung diseases amid ongoing focus on asbestos-related mesothelioma from classics like Wagner, Sleggs, and Marchand (1960).
2022Research Occupational and environmental lung diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Occupational and environmental lung diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers